April 7, 2024
E3 Pairing and Structural Mechanisms Underlying Anti-Tumor Activity of Clinical STAT3 Degrader KT-333
American Association for Cancer Research (AACR) 2024 Annual Meeting
Read More
March 8, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a Mouse Model of Atopic Dermatitis
American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More
March 8, 2024
Potent and Selective TYK2 degraders, Devoid of JAK Activity, Potently and Completely Suppress IL12/23 and Type I IFN Signaling Pathways
American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More
December 10, 2023
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Hematology (ASH) Annual Meeting and Exposition 2024
CTCL
LGL-L
PTCL
Solid Tumors
Read More
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 16, 2023
Development of KT-253, a highly potent and selective heterobifunctional MDM2 degrader, for the treatment of Acute Myeloid Leukemia
10th International MDM2 Workshop
Liquid Tumors
Solid Tumors
Read More
October 14, 2023
The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Solid Tumors
Read More
August 16, 2023
Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases
American Chemical Society (ACS) Fall 2023 Meeting
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
July 24, 2023
Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders
Gadiyar, V., Patel, G., Chen, J., Vigil, D., Ji, N., Campbell, V., Sharma, K., Shi, Y., Weiss, M., Birge, R., & Davra, V.
Read More